Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

格隆汇1月9日丨贝达药业(300558.SZ)公布，为进一步发挥贝达药业股份有限公司在生物医药领域的产 业优势，围绕高壁垒技术领域持续完善生态圈布局，近日，公司已与花园集团有限公司（简称"花园集 团"）完成股权转让交割，公司出资5,000万元人民币受让花园集团持有的杭州知兴制药有限公司（简 称"知兴制药"或"标的公司"）注册资本人民币200万元，投后总占比为20%。知兴制药专注于高端吸入 制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实验室到产业化 落地的能力。 知兴制药聚焦关键技术攻坚，已成功搭建国内一流的粉雾剂研发平台，精准突破1-5微米粒径控制、工 艺稳定性及装置协同等核心技术瓶颈。目前，其在研产品管线中适用于哮喘、COPD等适应症的三款产 品：丙酸氟替卡松雾化吸入用混悬液、吸入用丙酸倍氯米松混悬液及沙美特罗普卡松吸入粉雾剂均已完 成生物等效性（BE）试验，其中丙酸氟替卡松雾化吸入用混悬液申报上市在即。依托成熟的技术研发 平台与扎实的技术积累，知兴制药将聚焦跨国药企垄断的高壁垒品种、同步拓展改良型新药及创新药研 发，结合市场发展趋势梯度化布局多元化产品管线。 ...

Group 1: Automotive Industry - Foton Motor announced a cumulative sales of 650,053 vehicles in 2025, representing a year-on-year growth of 5.85%, with a production of 659,455 vehicles, up 7.95% from the previous year. Notably, new energy vehicles accounted for 101,200 units sold, marking an impressive growth of 87.21% [1] - The China Passenger Car Association reported that retail sales of new energy passenger vehicles reached 12.809 million units in 2025, reflecting a year-on-year increase of 17.6% [13] Group 2: Pharmaceutical Industry - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical, which focuses on high-end inhalation formulations. This investment is expected to enhance the company's new drug development capabilities and expand its strategic layout in disease treatment [2] Group 3: Real Estate Industry - R&F Properties reported a total sales revenue of 14.21 billion yuan for 2025, with a sales area of 1.8736 million square meters [3] Group 4: Technology and Digital Services - Kingsoft Office has signed a strategic cooperation memorandum with FPT, focusing on localizing WPS 365 in the Vietnamese market and enhancing user growth and joint solutions [4] - PhotonPay has completed a multi-million dollar Series B financing round led by IDG Capital, aimed at expanding its global payment network and upgrading its underlying technology infrastructure [8] Group 5: Utilities - Shenzhen Gas reported a total revenue of 29.796 billion yuan for 2025, with a net profit attributable to shareholders of 1.407 billion yuan, reflecting a year-on-year decline of 3.45% [5]

Core Viewpoint - The company has completed the equity transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in high-end inhalation formulations [1] Group 1: Company Investment - The company invested 50 million yuan to acquire the 200 million yuan registered capital of Zhixing Pharmaceutical [1] - This investment aligns with the company's long-term development strategy in the high-end inhalation formulation sector [1] Group 2: Industry Overview - Inhalation formulations are defined as drug delivery systems that utilize inhalation devices to administer medication to the respiratory tract, offering local or systemic therapeutic effects [1] - These formulations are recommended as the preferred treatment method for asthma and chronic obstructive pulmonary disease (COPD) in domestic and international guidelines [1] - Inhalation formulations are expanding into other fields, including vaccines and central nervous system applications, and are being explored for lung cancer treatment due to their targeted delivery and flexibility [1]

Core Viewpoint - The report highlights a significant outflow of main capital from various stocks in the Shanghai and Shenzhen markets, with 387 stocks experiencing net outflows for five consecutive days or more, indicating potential investment risks in these companies [1][2][3][4]. Group 1: Main Capital Outflow Statistics - The stock with the longest continuous net outflow is Dameng Data, with 23 days of outflows [1]. - Daqin Railway follows with 20 days of net outflows, totaling 2.711 billion yuan [1]. - The total net outflow for Daqin Railway over 20 days is the highest at 2.711 billion yuan, while Xiechuang Data has a net outflow of 1.914 billion yuan over five days [1][2]. Group 2: Stocks with Significant Outflows - The top stocks by net outflow duration include: - Daqin Railway: 20 days, 2.711 billion yuan, 18.68% of trading volume, -6.22% cumulative change [1]. - Dameng Data: 23 days, 0.503 billion yuan, 7.58% of trading volume, 14.15% cumulative change [2]. - Haima Automobile: 12 days, 1.626 billion yuan, 8.26% of trading volume, -18.59% cumulative change [1]. Group 3: Other Notable Stocks - Other stocks with notable outflows include: - Wuzhou Xinchun: 5 days, 1.574 billion yuan, 5.24% of trading volume, 11.62% cumulative change [1]. - Dongshan Precision: 6 days, 1.512 billion yuan, 6.91% of trading volume, -6.80% cumulative change [1]. - Shengtai Electronics: 10 days, 1.377 billion yuan, 8.47% of trading volume, -8.71% cumulative change [1].

人民财讯1月9日电，贝达药业(300558)1月9日公告，近日，公司已与花园集团完成股权转让交割，公司 出资5000万元受让花园集团持有的杭州知兴制药有限公司（简称"知兴制药"）注册资本200万元，投后 总占比为20%。知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与 生产体系，具备将产品从实验室到产业化落地的能力。目前，其在研产品管线中适用于哮喘、COPD等 适应症的三款产品：丙酸氟替卡松雾化吸入用混悬液、吸入用丙酸倍氯米松混悬液及沙美特罗普卡松吸 入粉雾剂均已完成生物等效性（BE）试验，其中丙酸氟替卡松雾化吸入用混悬液申报上市在即。 转自：证券时报 ...

Core Viewpoint - Beida Pharmaceutical has completed the equity transfer with Huayuan Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical for 50 million yuan, which will enhance its new drug development technology platform and expand its strategic layout in disease treatment [1] Group 1 - Beida Pharmaceutical invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [1] - Zhixing Pharmaceutical focuses on the development of high-end inhalation formulations and has established a comprehensive R&D and production system [1] - The investment does not constitute a related party transaction or a major asset restructuring, and does not require approval from relevant authorities [1] Group 2 - This investment will help Beida Pharmaceutical to broaden its strategic layout in the field of disease treatment [1]

贝达药业公告，公司出资5000万元人民币受让花园集团持有的杭州知兴制药有限公司注册资本人民币 200万元，投后总占比为20%。 ...

证券代码：300558 证券简称：贝达药业 公告编号：2026-001 贝达药业股份有限公司 关于投资杭州知兴制药有限公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 为进一步发挥贝达药业股份有限公司（以下简称"贝达药业"或"公司"）在 生物医药领域的产业优势，围绕高壁垒技术领域持续完善生态圈布局，近日，公司 已与花园集团有限公司（以下简称"花园集团"）完成股权转让交割，公司出资 5,000 万元人民币受让花园集团持有的杭州知兴制药有限公司（以下简称"知兴制 药"或"标的公司"）注册资本人民币 200 万元，投后总占比为 20%（以下简称 "本次投资"）。知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚， 已搭建完善的研发与生产体系，具备将产品从实验室到产业化落地的能力。 根据《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交易》等法律法规、 规范性文件及《贝达药业股份有 ...

Core Viewpoint - Benda Pharmaceutical's stock has shown a mixed performance with a year-to-date increase of 7.90%, but a significant decline of 12.97% over the past 60 days, indicating volatility in its market position [1]. Financial Performance - For the period from January to September 2025, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 669 million yuan, with 184 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - The stock's trading activity showed a net outflow of 9.349 million yuan from major funds, with significant buying and selling activity from large orders [1]. Company Overview - Benda Pharmaceutical, established on January 7, 2003, and listed on November 7, 2016, is primarily engaged in the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concepts such as ophthalmology, innovative drugs, and precision medicine [1].